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Summary: Arandomi~ed controlieddinical 
trhll of three fully, onll short course 
chemotherapy regimens of6, niont~ duration 
is being c~riductcd to ev!:,hlatespHt-dos'c 
d9,tl~le dr.u~· combinationsforthet~e~tmc?t 
oC:sputum 'P9s!tive pUI":",o~ar~:.tuberc~lo~~. 
Split, I and:: Split ~l regupens consist (jr, 
R:ifaJllpici~ and Ethambutol, qn JII"1e.d.~yail~! .. 
r~qMaiidanc)Pyrazl~ilamlde~n the .rie~t day, 
e~¢hcorilbinatiollgiven thdcea week dur111~ 
th~lnitial hltensive phase of 2or:3months, 
respectiv~ly;followed 'by Rifal13picillaml 
Isoniazid given twice a week' dlirln~ the 
continuation phase for the next 4 and 3. 
month~. respectively. Th~ con~rQJregimen. 
consists· of all the four drugs, Rifanipidp;. 
Isoniazid, Pyrazinamide and EthamhiJiiJl, 
giv~n together in a single dose thriCe~~e,e~' 
during thet~tenslve phase of Ilrst 2 months,' 
alid Rifampicin and Isonhlzidtwice a.:w~ek 
d~ring the~ontinuation phase. of n~xt 4. 
months. ti~ugs were given unde~. full 
supervision dm'ing the entire chemotherapy 
pei-iod of 6 months. Tbe findings upto tbe 
end of chemotherapy for 750 patient~ suggest. 
tha"tthe. response is slmil.ar in split and' 
l:ontrol reg'imens,a~ong p_ltients with' 
sensitive organisms and those with resistance, 
to Isoniazid alone. Among 'patients witb 
organisms resist~nt.to both Isomazld and 
Rifampicin, ~Imost all hud an unfavoun,b~e 
response. 'Adverse reactions \Vcre low and. 
similar in both split and control.regimens. 
Introd uction 
Several highly effcclive short course 
chemotllerapy regimens have becn evolved for 
Ihe trcaunent of sputum, positive pulmonary 
tuberculosis. In most of tllese regimens, four 
drugs, viz, Rifampicin(R), Isoniazid(II), 
Pyrazinamide(Z) and Strcplomycin(S) or 
EtllambuLO)(E) arc given togetl1er in a singk dosc 
cithcr daily or illlenniuently in ule initial phasc. 
The bnlk of the drugs to be consumed in a single 
dosc is, therefore, large and may affcct patient 
compliance. Furtller, the incidence of adverse 
reactions such as artllralgia and jaundice is higher 
with daily regimens. 
Hence. a study is being conduted whercin 
thc four drugs are split il1l.o two 2-d rug 
combinations, each combination gi~en on altcmalC 
days, tllus making each combination intermittent. 
The advantage of tlle splil regimens is lbat tllC 
bulk of the drugs in a single dose is .less and 
adverse reactions are cxpecled to be low. 'nlcse 
two fr;Clors togeuler will presumably help in 
improving patiel1l compliance. 
Study Subject" 
The patients were residents of either Madras 
or Madurai. and had come to tlle out-palicllls I I 
chesl clinics because of symptoms. Patients were 
eligible for inclusion in the sludy ilTespcetivc of 
previous chemotherapy, if they were agcd l2 
years or more, had at least 2 sputum cultures 
positive for M. IIlberclllosis, even Ihough admission 
to tlle study was based on smear posilivily, and 
were willing to altend Ule centre for superviscd 
chemotllcrapy for a period 'of 6 months. Patients 
witll diabetes, hypertcnsion, bleeding diathesis 
and extra pulmonary tuberculosis were not eligible 
for the study 
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Hegi Inen,	 j10plJl;t(ion consisled of 7,'i() P;(I1('11IS ilf wlll)I11 124 
were excluded for v:lrimls r<:,asons likc lIl:g,alive 
l';lticnt. were randomly allcleall'd, ~lralifJed culture on adl1li"slon, e;ldy de;llh, dC~llh due [0 
(Ill the oasis of duralioll of previ(1u~ c]l('![1o!lwrapy 110Il-luhcrClllolls causes ;tnd f( II haviug U\lssed 
and degree of SplJtllnl P()~ilivity. (() olle of the 25'!.- or more or dICn1l\lher;lpy There fl'111;lincti 
following (hree fully supervised f(:.!Cili\en~; or 6 ;J lotal of 626 p:lticnts in the :lIl:i1ysis. or these, 
months' (]llration. ij(),;{, had l)rg:1I1isll1s sensitive IlJ Tsonia/.id and 
Ri f;ullpicin, 1(i'l of p~lticnts b;}(l resistance to 
III the nrst regimen, 21{EJI ![-\ (;11 1)f.:lRII2 Isoniazid ;1I0IlC, O.YX. h;1(1 resist:lllee lol{if:unpicioll 
(split 1), during U1C' initi,d phasl:, Rifampicin anl1 alilnC Wid 3/;:' nf pa~ll:nts llJd resistance (0 hoth 
[Ul;llllbutol were given on olle day anl! Isolliazid ISOfii;I/.id 'Iud RiLunpicin ('L'ihh: I). 
and Pyrazinamide on lhe nex! day, lhrice a week 
for 2 months followed oy Rifampicin :uld Isoniazil1 During ehel1lotherapy, \ sputum .';pecimens 
twice a week for the next 4 mOJlths. The seL~ond ("rom each (lalicl1i Wt'iT examincd hI' cullurc for 
regimen, 3RE311Z3 «llt)/3RH2 (s(llil II), was M. IlIhl'r(lIfn~i.l' every monlh. 'l"1lt: pW(lortiol1 of 
simi1:tI to regimen I, OUI the inili:d ph:Ise was patienls willl ncg;llivL: culLure :II first rnonih was 
for 3 months, followeL! by 3 nlOllllis in the 2;..(% and 30'7, ill splil I and [I regimens, 
continuation phase. The third regimen, (2RLlIJJI re~pcclivcly and 2X'i(. in (he. cOlltml regimen. By 
4RH2), was U1C eonu'ol reg'lTllen "vhcft~ :111 four secllnd month, It Iud gnllt: up (0 SO·gyX·, hOlll 
drugs were given together ill :1 slIlgle Josc Ihrice 3re! 10 61h mO!1lh il wa~ ()5 - 1.)<)rJ,•. Tilus Ule speed 
a wCt:k for 2 mOTllhs followed by l{if.1mpiein alll! of SPUlul11 conversion was similar in all tJ1C 3 
Isoniazid twice a week for next 4 months. Tile rer-iHlens (T~lblc 2) 
dOS:lgCS were same for all Ihe lhrec regimens ill 
oOlh Ill(: phases. For (lalienls \ycigl1illg ·to kg or Pruportiull or P:IIICIlIS who received mon: 
\<:ss, rifampicin 450 mg, FthamblJlo) I (JO() mg Ih,m XO'/o or their prL'scrihcd chclIwlherapy was 
~lnd Pyrazinamide 1.5 g were givcn. l'nr patients iQ(!\: and (;5'7, ill split I and II regimcns, 
weighing more Lllan 40 kg. the dosage~ were 600 respeclivc.ly :i1lll ~2/~;, in lhc CO11 lJ'o I regimen. 
mg, 1200 mg and 2 g, respecllvely. lsol1i:1Zid was Even though pallClll~ had 10 at lend daily for the 
glvCII in a fJ~'1 dose of 600 In.!:', iae"pL'uive of inili:Jl 2 10 3 (lwnlhs III the split regimens, tJle 
hody weigh!. drug. n;,gul~lrily \\';l~ "imil;lr til IIl:ll or conlrol 
regimcn where thcy h;ld In attend thrice :t week 
Results during this period. (Tahlc 3). 
The findillgs of U1C iUlerr111 an:llysis uplo A Ll\(llirabic h:lclcriologictl rc:,;pollse at lhe 
Ule elld of el!clIlOlherapy are prcsenled here. The end of L'llCl1liJ1hcr:lpy was defmcd :t~ ;Ill cultures 
Table 1. Study popubtlion 
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Table 2. Culture negativity (%) during treatment among p~ltients with initial drug sensitive 
organisms 
Months afler start 
of U'calmcnt 
2 RF311Z3(all)/ 
4RH2 
(Splil I) 
3RE31IZ3(:~Il)/ 
3RH2 
(Split II) 
2REHIJ 
4RH2 
(Coll/rol) 
1 
2 
3 
4 
5 
6 
28 
80 
97 
97 
95 
97 
30 
83 
96 
99 
98 
95 
29 
82 
96 
98 
96 
98 
Range of 
Palienls 
171 - 173 168 - 169 161 - 162 
Table 3. l'ercenhlge of chemotherapy received during phases I & n 
Treatment NUlllber of patiellts 
rece.i ved(%) 
2RE3HZ3(all)/4RH2 ~RE311Z3(alt)I3RH2 2 REIlZ3/4 RH2 
(Split I) (Split 11) (Conlrol) 
~ 80 195(82)" 204(85) 200(82) 
50 - 79 28(12) 24(10) 22(9) 
< 50 1«1) 0(0) 1«1) 
Missed conlinuously 14(6) 13(5) 20(8) 
for >1 month 
TOlal 238 241 243 
., Percentages in pal'cl\(hC'~is 
Table 4. Response at HIe end uf dl(:motherapy amnl1g patients with initial drug scnsitiw OJ·g.misms 
Response Number of paticnts 
2Rr:l ZI-l3 (a 11)/ 
4RH2 
(Splir I) 
3RF.3 HZ3(all)/ 
3RH2 
(Split II) 
2REHD/ 
4Rll2 
(Control) 
Favourable 
Doublful 
UIIfa ,'ourable 
163(94)" 
6(3) 
4(2) 
158(93) 
9(5) 
2(1) 
152(94) 
10(6) 
0(0) 
Torat 173 169 162 
" Pcrcenlages in parcnrhc-'is 
negative in the lasl two mOllths of chemotherapy. 
An unfavourable bacteriological response was 
defined as 2 or more cultures being positive in 
the last two monllJs of trca(m(~llt including one 
culLure in tlle last Illonlh Gild a least one cullure 
growing 20 colonies or more. Jr. addition, p<I(ieIlIS 
who had a change of treatment for pcrsiSlcllI 
cullUre p()~itivity. or radiographic or clinical 
deterioration and those who cJiecJ of tuberculosis 
were also classified as having had an unfavourable 
response. Those whO did not fit into these critcri'a 
were classified as having doubtful rcsponse. 
At tile cnd of dlcll1olhcrapy, ,unong pntienls 
-------------------------------------------
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wilh drug sensitive org;L1lblllS, J favourable 
response was ohtained in 94{/c allCl 93'10 in split 
I and II regimens, respectively and 94% ill tile 
control regimen, It can he ohserved lilat the 
response at thc L:nd of (reatment is not very much 
alTecled hy splilling the drugs, All those with 
doubtful response converted by 7lh monlh wilhout 
additional chemotherapy. Only Y/" and I % of 
patients, respectively in the split I anc! 11 regimens 
had unfavourable response Cfable 4), 
i Among those with organisms resistant to 
Is( niazid alone, favourahle response was seen in 
n% and 8JC:{., respectively in split I and II 
regimens and 74% in tJle control regimen, while 
unfavourable response was seen in 19 fk), 14% and 
21% respeuively in the three regimens, Out of 
U1CSC pa(ient~ wilh lInfavour,lble response, one 
died and ~ill the others had chan~e of Ire:lIrnclll 
for persistent CullllrL: positivily (T:lbll' 5) 
There were 19 patienls with organisms 
rcsi~,t:l1H 10 botll!slllli,IL,id and RiLunpicin, Except 
one, all the otllcrs had an unfavourahle response, 
Two palients who kid rcsisl;lIlce (0 Rifampicin 
alone had a favourable re~ponse, 
Adverse r~adions 
;\dver~e reaCtions CIIClllllllL:red during 
che!lH1lllcrapy wne mainly ga~lm-intcstinal 
symptoms, anhr:llgi;I, Iiep;llitis and cutaneous 
rc,,('lions. Prupnniolls of' p,\liellts reporting with 
allY of these compl:-lillts were 11 %, 18% and 
17%, respeclively, in Uw 3 regimens. The difference 
between splil regimens and control regimen was 
nOl sialisticllly sigllilicllll (Table 6), Majority of 
the adverse reactiolls were managed 
Syl11ptOlll,llic,i1ly, IVll1dil'ic<llion oj' chclllotherapy 
Ii<ld to he dOlle (\lily in 14 p;llicnls, One patient 
(split I) deVeloped hypersensitivity rl';luion during 
Ihe third ..."cd:. or Ire;ltml'lll in Ihe I'onn of severe 
11llrllillg all nvC!' with hot flushes. when' he was 
receiving Isoniazid and Pyr~l,-in~Lll1idc. Altempts 
Table 5, Ih'sporlsC at the end of chcmotherHpy alllong patients with illitial II resistant organisms 
Ii 
2KE~ II/.'("lf)/~ RI 12 <RE 1117.3(,,11 )/1, R112 2RLHI I-I R1l2f: 
;Splil t) (Srli1 I\) (\('"11'01) 
~o. IX, NtJ. 'i;', "'0, % 
fa \'olJrahle 
Doubtful 
Unf"vourabk 
21 78 
~ 
JI} 
29 
2 
5 
81 
I) 
I~ 
28 
2 
74 
5 
21 
36 38I~ 
J 
TaMe 6. Adverse rC,l\; lions 
TOI"I 
No, of 
r:lIielllS AllY Gastro­ Arlhr- CllfaJl- Ciiddi- He",,­
inh..~$linal algia ~OllS ncS:i litis 
2RI-,1I1LJ (alr)1 
4RI12 
(Split 1) 2,11, 27( I 1)* 7 2 
3RE3[Iz:!Utll\ 
)RJ 12 
(Splil 1)) 2.\.\ 4)( I R) 13 19 
2KHIDI.\RI12 
(COllfrol) 2H .\[(17) 20 7 'I 4 
r't~rc('Il(<l£.('.') in r~lr.:nlht:'si~ 
"+: lll('lud ...·:j "fJu'l syndr()m~. hYI.h::rSt'IlSIlJvily r....~~I1.:lron and p('riph~":ll Ih;'uH\pathy 
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for desensitization for both Isoniazid and 
Pyrazin[illlide failed and Ule drugs were terminated. 
H.ifampicin was terminated in three patients. One 
patient (control) developed itching wiOI puq)uric 
rashes Juring tlle third week of treatment, second 
patient (control) had 'fiu' syndrome from Ole 
second dose cf trealmcnt (Ulis pal icnt had received 
Rifampicin uutside before admission to tJ1C sWdy) 
ant! U1C third patient (split II) hat! fever and 
brcallllessness after receiving Rifampicin and 
Ethambutol combin,ltion, devcloped 
hypersensitivity reaction while IHlder observation 
in the clinjc after receiving Rifampicin. Nine 
p;1tients had interruption of drugs, seven for 
jaundice (2 split I, 4 split II, 1 control). Of thesc, 
five p;1tients developed jaundice during the inilial 
intensive phase. Rifampicin and Isoniazid (and 
Pyrazin,unide in Ole initial phase) were withheld 
teinporarily and reintroduced after subsidence of 
jaundice wiUlOUI any problem. The otl1t:r two 
patients had interruption of the offcnding drug 
for severe glossitis in ODe and itching in the otller. 
For tJlese two patienL) nJ$O, drugs were reintroduced 
without any problem. One patie-nt (control) had 
severe gastrointestinal prohlem and the dosage of 
thc drugs had to be reduced. 
Disl"Ilssion 
Several studies havc'shown UW! short course 
regimens u.jng the four drugs viz, Rif:unpicin, 
Isoninzid, Pyrazin;unide and Streptomycin or 
Hkunbulol during the intensive phase me effective 
in the tlC<Hment of sputum positive pulmonary 
tuberculosis '·J 1Iowever, in these regimens patients 
find it difficult to consume t]le druQS given eitller 
daily or intermi((ently becausc of the bulk. An 
iII vifro study done at our centre has dem mstrated 
Ihat splitting the 4 drugs REIIZ> into 2 split drug 
combinations of RE and HZ may not affect lhe 
b;1ctcricidal action of tile n:g.imens~. Furtller, it 
has alrc;1dy been reportecI from experimental 
murine tuberculosis that split dose alternating 
regimens are as effective as giving al1 the 4 drugs 
together~. Thus, it was assuilled that anti­
tuberculosis drugs given in split coinhill<llion 
wOllld be clTclive in hUI1l;11l bbngs as well. 
llence. the Tuberculosis Research Ccnlre 
COlldllctcd a conlrolled cliniC;11 trial in sputUJlI 
po ilive pulmonary tuberculosis where the 4 cInJg 
comhillation was split into two 2-drug 
combinations, combination given on alternate 
each days, thus making each combination 
intennittent. 
This study, as far as w~ i.ln~ aWi.lre, is 
unique because split drug combinations were 
used in a controlled clinical trial in sputum 
positi,,&-. pulmonary tuberculosis patients for 
the first time. 
The r~sults indicate tlUlt in patients with 
initially drug sensitive organisms, the split 
regimens have :i high stcrilil.ing activity, 
producing sputum conversion in 80 to 83% by 
2 months, which is similar to that in the 
control regimen. This result compares well 
with the findings of 80 - 87% conversion in 
East Arric:m paticnts treated with short course 
(.·hemotherapy6-7. At the cnd of chemotherapy, 
a favour~lble response (all l:ultures negativ~ in 
the last two months of chemotherapy) was 
observed in 93 • 94% in split regimens which 
is again similar to that in the control regimen 
(Table 4). This tinding is in conformity with 
the observations rr'om i" vitro studies, animal 
experiments and ill Ilivo studies4.~. K. 9. 
Among patients WiOl bacilli rcsistant to 'II' 
alone, favourable responsc was observed in 78% 
and 81%, respectively, in split I and II regimens 
which is similar to the 74% in control regimen, 
whereas in patients will! organisms resistant to 
hoth I:-;oTlazid and Rifampicin almost all hGd an 
unfavourable response. 
Adverse rcactions were generally low and 
similar in hath split and control regimcns. PaLicnL<; 
were not questioned about symptoms of drug 
tOxicity, but every spontaneous complaint was 
recorded after careful questioning by a physican. 
Main adverse rcactions encountered werc gastro­
intestinal symptoms, arthralgia, hepatitis and 
cutaneous reactions. Proportions of patients with 
any of these complaints were II % and IWlo in 
split rcgimens and 17% in the control regimen. 
This is Illuch lower than IbM observed at llle 
centre in c:lrlier sec regimens wilh daily lreatment 
in the initial intensive phase ' . Modification of 
chemotherapy (tenllil1alion, interruption, reduction) 
were necessary in only 14 cases. 
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Thus. 1J1cre docs not appear to be any 
tliffcrence cilhn in lllL: efficl<':y of regimens or 
loxicity whcn drugs are :ldmlillstcrcd as split 
re(lill1\.~ns (altcm:lldy) compared [{ (living all the 
4 drugs togelher. All patients arc hcinu followed­
lip (0 aSsess llle erticacy of the douhle drug 
combination regimens with long lenn follow up 
for possible relapses. It Illay be presumed thaI 
the relapses would be minimal sincc the culture 
negativity rate. at the end of 2 months of 
inlensive chemotherapy are of Ule order of SO 
to 83%8. 
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